Michael Hallek
MD
Director, Department of Internal Medicine I
👥Biography 个人简介
Michael Hallek at Cologne established the FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy regimen as a CLL standard through the CLL8 trial — which remained the benchmark for over a decade. He chairs the German CLL Study Group (GCLLSG) and has been involved in virtually every subsequent pivotal CLL trial, from CLL10 to CLL14. His longitudinal contributions to CLL represent among the most comprehensive in the field.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Michael Hallek 的研究动态
Follow Michael Hallek's research updates
留下邮箱，当我们发布与 Michael Hallek（University Hospital Cologne）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment